Physician profile

Eric Hines

Family Medicine · Sparta, MO

NPI 1689289282

$2,079.22

in general payments reported to CMS, 2019-2025

24 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $278.53 2020-2021
Lilly USA, LLC $273.23 2020-2022
Novo Nordisk INC $232.43 2021
Janssen Pharmaceuticals, INC $196.42 2021-2022
Teva Pharmaceuticals USA, INC. $166.46 2021-2022
Astrazeneca Pharmaceuticals Lp $122.01 2021-2022
Takeda Pharmaceuticals U.S.A., INC. $115.42 2021-2022
Glaxosmithkline, LLC. $93.95 2021-2022
Collegium Pharmaceutical, INC. $89.10 2020-2021
Boehringer Ingelheim Pharmaceuticals, INC. $85.00 2020-2022
Novartis Pharmaceuticals Corporation $70.84 2021-2022
Otsuka America Pharmaceutical, INC. $49.15 2021-2022
Genentech USA, INC. $46.85 2022
Mylan Specialty L.P. $38.80 2021
Allergan, INC. $38.69 2020-2021
Show all 24 companies
CompanyGeneral paymentsYearsTop products
Daiichi Sankyo INC. $33.95 2022
Jazz Pharmaceuticals INC. $29.07 2020-2022
Corium, LLC $26.80 2021-2022
Organon LLC $17.31 2022
Astellas Pharma US INC $16.61 2021
Ultragenyx Pharmaceutical INC. $16.03 2021
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $14.96 2022
Amgen INC. $13.88 2021
Adlon Therapeutics L.P. $13.73 2020

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Eric Hines

$2,079.22

in general payments reported 2019-2025

Years
2020-2022
Top company
Abbvie INC.

https://glasscript.com/doctor/8002511/eric-hines

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.